Some early gene-based “precision therapies,” such as quinidine for KCNT1-associated epilepsy with migrating seizures in infancy, have now failed to confirm high expectations in larger patient groups, and common antiseizure medications have been shown to be superior to precision therapy approaches [10]. This evidence concerns the gene KCNT1 and epilepsy.